Prostate cancer screening remains controversial in the medical field. While screening men above 50 years can impose overdiagnosis and overtreatment, targeted screening of males with pathologic variants of genetic mutations is evolving and viewed as sensible. Identifying such patients requires genetic testing in males having family history of prostate cancer or certain ethnicity. Such strategies will likely occur as routine practice once favorable results of ongoing studies assessing genetic predisposition are released.
The Canadian journal of urology. 2019 Oct [Epub]
Thomas J Polascik, Hazem Orabi
Division of Urology, Duke Cancer Institute, Durham, North Carolina, USA.